Natus announces entry into Point-of-Care EEG with launch of BrainWatch
The introduction of BrainWatch solves vital needs identified by customers desiring a point-of-care solution that would be easy to use and interface with NeuroWorks®, the EEG platform trusted by more health systems and small hospitals worldwide.
"In this day and age, brain-health professionals, including neurologists and EEG technicians, are in scarce supply," said Natus CEO
BrainWatch can be set up in less than five minutes, allowing quick intervention in acute care environments and streamlining treatment decisions with neurology support to improve patient care.
By leveraging the NeuroWorks platform, BrainWatch offers a familiar review experience with remote neurologist collaboration 24/7 from any web browser.
BrainWatch delivers the most complete ACNS-compliant rapid EEG solution for Critical Care, enabling full referential analysis. It also offers exclusive on-device software with integrated FDA-cleared Persyst algorithms for seizure detection and seizure burden, built on the industry-leading Persyst 15.
"We've found the EEG signal quality from the small, wearable, and wireless BrainWatch device to be impressive," said Dr.
ABOUT NATUS
Natus is trusted by healthcare providers around the globe as the solution source to screen, diagnose, and treat disorders affecting the brain and neural pathways. The best-in-class Natus solutions, including service, field support and education, enable clinicians to advance their standard of care, improving patient outcomes and quality of life. For more information on Natus, please visit natus.com/neuro.
CONTACT INFORMATION:
Phone: +1 612 528-1332
Email: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/natus-announces-entry-into-point-of-care-eeg-with-launch-of-brainwatch-302460438.html
SOURCE Natus Medical Incorporated
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The Center for Food Safety: Trump Administration Sued for Approving 'Forever Chemical' Pesticide Trifludimoxazin
- So-Young Reports Unaudited Second Quarter 2026 Financial Results
- Oppenheimer Welcomes Joel Berry II and Expands North Carolina Private Client Team Focused on Advising Athletes
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share